Gene Editing in Human Induced Pluripotent Stem Cell Using Prime Editing
Author:
Zhou Miaojin,Hu Zhiqing
Reference25 articles.
1. Warren L, Manos PD, Ahfeldt T, Loh YH, Li H, Lau F, Ebina W, Mandal PK, Smith ZD, Meissner A, Daley GQ, Brack AS, Collins JJ, Cowan C, Schlaeger TM, Rossi DJ (2010) Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 7:618–630. https://doi.org/10.1016/j.stem.2010.08.012 2. Doi D, Magotani H, Kikuchi T, Ikeda M, Hiramatsu S, Yoshida K, Amano N, Nomura M, Umekage M, Morizane A, Takahashi J (2020) Pre-clinical study of induced pluripotent stem cell-derived dopaminergic progenitor cells for Parkinson’s disease. Nat Commun 11:3369. https://doi.org/10.1038/s41467-020-17165-w 3. Nenasheva T, Gerasimova T, Serdyuk Y, Grigor'eva E, Kosmiadi G, Nikolaev A, Dashinimaev E, Lyadova I (2020) Macrophages derived from human induced pluripotent stem cells are low-activated “naive-like” cells capable of restricting mycobacteria growth. Front Immunol 11:1016. https://doi.org/10.3389/fimmu.2020.01016 4. Gao Y (2023) Using human iPSC-derived peripheral nervous system disease models for drug discovery. In: Handbook of experiment pharmacology. https://doi.org/10.1007/164_2023_690 5. van der Wal E, Iuliano A, In’t Groen SLM, Bholasing AP, Priesmann D, Sharma P, den Hamer B, Saggiomo V, Kruger M, Pijnappel W, de Greef JC (2023) Highly contractile 3D tissue engineered skeletal muscles from human iPSCs reveal similarities with primary myoblast-derived tissues. Stem Cell Reps 18:1954–1971. https://doi.org/10.1016/j.stemcr.2023.08.014
|
|